As clinicians, we often encounter patients with elevated liver enzymes, a clinical puzzle that requires careful interpretation and management. The challenge lies in the broad differential diagnosis, which includes both benign and serious conditions. This article aims to provide a comprehensive approach to managing such cases.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the most commonly evaluated liver enzymes. They are sensitive indicators of hepatocellular injury, but not specific for a particular etiology. Thus, the interpretation of elevated liver enzymes should be done in clinical context, considering patient's history, physical examination and other laboratory findings.
Common causes of elevated liver enzymes include alcohol consumption, viral hepatitis, and non-alcoholic fatty liver disease. Other possibilities include drug-induced liver injury, autoimmune hepatitis, metabolic disorders, and less commonly, malignancies. It is essential to perform a thorough evaluation to identify the underlying cause and to guide management.
Once the etiology has been identified, the management should be tailored accordingly. In cases of alcohol-related liver disease or non-alcoholic fatty liver disease, lifestyle modifications are the cornerstone of treatment. Antiviral therapy is indicated for viral hepatitis. For drug-induced liver injury, discontinuation of the offending drug is usually sufficient. In all cases, patient education and regular follow-up are crucial.
Elevated liver enzymes represent a common yet complex clinical issue. A systematic approach to interpretation and differential diagnosis, followed by an etiology-based management, is the key to optimal patient care. As we continue to advance in our understanding and technology, the enigma of elevated liver enzymes will hopefully become less intimidating, leading to improved patient outcomes.
1.
Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety
2.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
Low Income, Education Tied to Depression in Older Adults
5.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
1.
Bridging Disciplines: Medical Oncology vs Surgical Oncology in the Era of Multidisciplinary Cancer Care
2.
Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
5.
Personalizing Cancer Care: Microbiome Advances, Challenges, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
Navigating the Complexities of Ph Negative ALL - Part XV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation